10-K/A: Carmell Corporation Files Amended 10-K to Include Part III Information and Updated Certifications

Carmell Corporation has filed an amendment to its annual report to include information about directors, executive compensation, and other corporate governance matters, as well as updated certifications from its CEO and CFO.

Summary

• Carmell Corporation filed an amendment to its annual report on Form 10-K to include information previously omitted regarding directors, executive officers, and corporate governance.
• The amendment also includes updated certifications from the company's principal executive officer and principal financial officer.
• This filing was necessary because the company's definitive proxy statement for the 2024 annual meeting will not be filed within 120 days of the fiscal year-end.
• The original Form 10-K was filed on April 1, 2024, and this amendment should be read in conjunction with that original filing.
• The company's common stock is traded on the Nasdaq Stock Market under the ticker symbol CTCX.
• As of April 24, 2024, there were 20,730,559 shares of common stock outstanding.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, but the late proxy statement and late filings by directors and officers are a concern. The company's financial situation and related party transactions also warrant caution.

Positives

• The company has a diverse board of directors with extensive experience in healthcare, finance, and operations.
• The company has implemented a non-employee director compensation policy to attract and retain qualified board members.
• The company has a 2023 Long-Term Incentive Plan to align the interests of employees and stockholders.
• The company has a code of ethics that applies to all employees, officers, and directors.

Negatives

• The company's definitive proxy statement will not be filed within the required 120-day timeframe.
• Several directors and executive officers filed late Form 4s and Form 3s related to stock transactions.
• The company did not pay performance-based cash bonuses to NEOs for 2023 to conserve cash.
• The company had unpaid salary and consulting fees for some executives and consultants in 2022 and 2023.
• The company has related party loans with a total principal outstanding of $5,610,000 as of December 31, 2023.

Risks

• The company's failure to file its definitive proxy statement within the required timeframe could lead to regulatory scrutiny.
• The late filings of Form 4s and Form 3s by directors and officers could indicate weaknesses in internal controls.
• The company's decision not to pay performance-based bonuses could impact employee morale.
• The related party loans and transactions could pose potential conflicts of interest.
• The company's reliance on related parties for services could create operational risks.

Future Outlook

The document does not contain specific forward-looking statements or guidance.

Management Comments

• Rajiv Shukla, the CEO, has extensive experience in healthcare investments and operations.
• The board believes that each director is qualified to serve based on their experience and expertise.

Industry Context

This filing is a standard regulatory requirement for publicly traded companies and provides transparency regarding the company's leadership and governance. The company operates in the healthcare sector, which is subject to significant regulatory oversight and scrutiny.

Comparison to Industry Standards

• The executive compensation structure, including base salary, bonus opportunities, and equity awards, is generally consistent with industry standards for publicly traded companies.
• The board composition, with a mix of independent directors and individuals with relevant industry experience, aligns with best practices in corporate governance.
• The company's use of a long-term incentive plan is a common practice to align the interests of management and shareholders.
• The related party transactions and loans are disclosed, which is a standard practice, but the amounts and nature of the transactions may warrant further scrutiny compared to industry peers.

Management Changes

Corporate Governance

Related Party Transactions

• The company has related party loans with Burns Ventures, LLC, with a total principal outstanding of $5,610,000 as of December 31, 2023.
• The company uses OrthoEx for 3PL services, and a former executive has an equity interest in OrthoEx.
• The company uses Ortho Spine Companies, LLC for consulting and marketing services, and Ortho Spine is owned by one of the company's advisors.

Stakeholder Impact

• Shareholders will be impacted by the information provided in this amendment, including details on executive compensation and corporate governance.
• Employees will be impacted by the company's compensation policies and the code of ethics.
• Customers and suppliers may be indirectly impacted by the company's financial performance and operational decisions.
• Creditors will be impacted by the company's related party loans and overall financial health.

Next Steps

• The company needs to file its definitive proxy statement for the 2024 annual meeting.
• The company should address the late filings of Form 4s and Form 3s by directors and officers.
• The company should continue to monitor and manage its related party transactions and loans.

Key Dates

Keywords

corporate governance, executive compensation, directors, stock options, financial reporting, related party transactions, Sarbanes-Oxley Act, Nasdaq, Form 10-K, proxy statement